Search results
Can Rishi Sunak turn it around?
The New Statesman· 4 days agoRishi Sunak delivered another solid performance in last night’s BBC head-to-head with Keir Starmer, perfecting his springy if supercilious debating...
The Tory media has gone into meltdown
The New Statesman· 3 days agoThe thing no one tells you about the stages of grief is that they are not, in fact, stages. This exhausted government has not left this mortal plane...
Why Roger Deakin’s Waterlog will change your life
The New Statesman· 5 days agoThe book was a bestseller upon release, and Deakin – who died in 2006, at 63, from a brain tumour – was respected as an environmentalist, documentary...
The new Europe chooses its leaders
The New Statesman· 5 days agoUrsula von der Leyen, Kaja Kallas and António Costa have been selected for the bloc’s top jobs.
Left-behind Britain
The New Statesman· 4 days agoJulius Nyerere became the first president of Tanzania, and Lee Kuan Yew the first prime minister of self-governing Singapore. Nyerere and Lee may have...
The Policy Ask with Paul McNamee: "The prospect of Rachel Reeves becoming the first female...
The New Statesman· 4 days agoPaul McNamee is the director of Labour Climate and Environment Forum. This has included advising on...
Joe Biden's last debate
The New Statesman· 4 days agoTwo things are clear after watching last night’s debate: Donald Trump should not be the next American president – and nor should Joe Biden. For months...
The risk of deepfakes deciding elections is real
The New Statesman· 3 days agoEarlier this year I realised, to my profound disappointment, that I hadn’t really been listening to Arnold Schwarzenegger. For a week I listened to a...
Welcome to the realm of the thought experiment
The New Statesman· 5 days agoWhat do a hurtling trolley, a shallow pond and a famous violinist all have in common?
AstraZeneca announces positive bladder cancer trial results, Landsec raises Bluewater stake
ShareCast· 6 days agoThe FTSE 100 is expected to open 13 points lower on Tuesday, having closed up 0.53% on Monday at 8,281.55. AstraZeneca announced on Tuesday that a recent trial revealed that ‘Imfinzi’, or durvalumab ...
